Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tafenoquine Succinate

FDA-approved product (tablet, oral), marketed as Arakoda, Krintafel.

Registered studies
42
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tafenoquine Succinate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria
  • Plasmodium vivax malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Aminoquinolines
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BA07

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

42registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tafenoquine Succinate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tafenoquine Succinate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria

    NCT07430592 · start 2026-10-01

    Registered record
    Registry ID
    NCT07430592
    Conditions
    Malaria; Malaria Vivax; Radical Cure
    Interventions
    SJ733/TQ placebo; CQ/TQ Placebo; CQ/TQ; SJ733 (3-day)/TQ; SJ733 (2-day ) /TQ; SJ733(1-day)/TQ
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2028-11-20
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Malaria Vivax; Radical Cure
    InterventionSJ733/TQ placebo; CQ/TQ Placebo; CQ/TQ; SJ733 (3-day)/TQ +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Tafenoquine and ACTs (TADORE- Plus)

    NCT07060794 · start 2026-06

    Registered record
    Registry ID
    NCT07060794
    Conditions
    Vivax Malaria
    Interventions
    Tafenoquine plus DHA-Piperaquine; Tafenoquine plus Artesunate-pyronaridine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-06
    Completion
    2028-06
    Enrolment
    507

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVivax Malaria
    InterventionTafenoquine plus DHA-Piperaquine; Tafenoquine plus Artesunate-pyronaridine
    PhasePhase 4
    Registry statusNot yet recruiting

  • Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax

    NCT07533136 · start 2026-05-01

    Registered record
    Registry ID
    NCT07533136
    Conditions
    Uncomplicated P. Vivax Mono-infection
    Interventions
    Tafenoquine (TQ); Chloroquine (CQ); Dihydroartemisinin-piperaquine (DHA-PPQ); Artemether-lumefantrine (AL)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-05-01
    Completion
    2029-05-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated P. Vivax Mono-infection
    InterventionTafenoquine (TQ); Chloroquine (CQ); Dihydroartemisinin-piperaquine (DHA-PPQ); Artemether-lumefantrine (AL)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults

    NCT07373743 · start 2026-05

    Registered record
    Registry ID
    NCT07373743
    Conditions
    Pharmacokinetic in Normal Population
    Interventions
    Tafenoquine Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2026-05
    Completion
    2027-03
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetic in Normal Population
    InterventionTafenoquine Oral Tablet
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Postpartum 8-aminoquinoline Breast Milk Study

    NCT07060404 · start 2026-04

    Registered record
    Registry ID
    NCT07060404
    Conditions
    Drug Pharmacokinetics in Healthy Volunteers
    Interventions
    Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water; Daily primaquine 1 mg/kg per day for 7 days given with food and water; Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-04
    Completion
    2027-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Pharmacokinetics in Healthy Volunteers
    InterventionDaily primaquine (0.5 mg/kg per day) for 14 days given with food food and water; Daily primaquine 1 mg/kg per day for 7 days given with food and water; Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria

    NCT07403643 · start 2026-04

    Registered record
    Registry ID
    NCT07403643
    Conditions
    Uncomplicated Malaria
    Interventions
    Single dose tafenoquine (10 mg/kg); Dihydroartemisinin-piperaquine (DHA-PPQ); Artemether + Lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-04
    Completion
    2026-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated Malaria
    InterventionSingle dose tafenoquine (10 mg/kg); Dihydroartemisinin-piperaquine (DHA-PPQ); Artemether + Lumefantrine
    PhasePhase 4
    Registry statusNot yet recruiting

  • B-FREE Chronic Babesiosis Study

    NCT06656351 · start 2025-11-18

    Registered record
    Registry ID
    NCT06656351
    Conditions
    Chronic Babesiosis
    Interventions
    Tafenoquine 100mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-11-18
    Completion
    2027-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Babesiosis
    InterventionTafenoquine 100mg
    PhasePhase 2
    Registry statusRecruiting

  • Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children

    NCT07052162 · start 2025-10-20

    Registered record
    Registry ID
    NCT07052162
    Conditions
    Pharmacokinetics of Tafenoquine
    Interventions
    Single dose tafenoquine (10 mg/kg) given with water; Single dose tafenoquine (10 mg/kg) given with fat
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-10-20
    Completion
    2026-03
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics of Tafenoquine
    InterventionSingle dose tafenoquine (10 mg/kg) given with water; Single dose tafenoquine (10 mg/kg) given with fat
    PhasePhase 4
    Registry statusRecruiting

  • Vivax Elimination With Tafenoquine (VET) Study

    NCT06575647 · start 2025-02-19

    Registered record
    Registry ID
    NCT06575647
    Conditions
    Malaria; Malaria, Vivax; Plasmodium Vivax; Plasmodium Vivax Malaria
    Interventions
    Tafenoquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2025-02-19
    Completion
    2025-10-04
    Enrolment
    1,242

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; Malaria, Vivax; Plasmodium Vivax; Plasmodium Vivax Malaria
    InterventionTafenoquine
    PhasePhase 4
    Registry statusCompleted

  • An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older

    NCT06666491 · start 2024-11-13

    Registered record
    Registry ID
    NCT06666491
    Conditions
    Malaria, Vivax
    Interventions
    Tafenoquine; Primaquine; Chloroquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-11-13
    Completion
    2026-05-25
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Vivax
    InterventionTafenoquine; Primaquine; Chloroquine
    PhasePhase 3
    Registry statusRecruiting

  • FocaL Mass Drug Administration for Vivax Malaria Elimination

    NCT05690841 · start 2024-10-14

    Registered record
    Registry ID
    NCT05690841
    Conditions
    Plasmodium Vivax Malaria; Malaria
    Interventions
    Focal Mass Drug Administration (fMDA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-10-14
    Completion
    2027-05-01
    Enrolment
    7,530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Vivax Malaria; Malaria
    InterventionFocal Mass Drug Administration (fMDA)
    PhasePhase 3
    Registry statusRecruiting

  • Southeast Asia Dose Optimization of Tafenoquine

    NCT04704999 · start 2024-07-22

    Registered record
    Registry ID
    NCT04704999
    Conditions
    Plasmodium Vivax Malaria
    Interventions
    Tafenoquine; Chloroquine; Artemether 20 mg-Lumefantrine 120 mg; Primaquine; Dihydroartemisinin 40 mg-Piperaquine 320 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-07-22
    Completion
    2028-02-07
    Enrolment
    820

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Vivax Malaria
    InterventionTafenoquine; Chloroquine; Artemether 20 mg-Lumefantrine 120 mg; Primaquine +1 more
    PhasePhase 4
    Registry statusRecruiting

  • Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis

    NCT06207370 · start 2024-06-17

    Registered record
    Registry ID
    NCT06207370
    Conditions
    Babesiosis
    Interventions
    Tafenoquine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-06-17
    Completion
    2027-07-01
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBabesiosis
    InterventionTafenoquine; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria

    NCT06148792 · start 2024-05-10

    Registered record
    Registry ID
    NCT06148792
    Conditions
    Vivax Malaria
    Interventions
    Tafenoquine; Primaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-05-10
    Completion
    2027-03-01
    Enrolment
    1,090

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVivax Malaria
    InterventionTafenoquine; Primaquine
    PhasePhase 3
    Registry statusRecruiting

  • Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru

    NCT05361486 · start 2023-08-28

    Registered record
    Registry ID
    NCT05361486
    Conditions
    Malaria, Vivax
    Interventions
    Tafenoquine (TQ)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-08-28
    Completion
    2024-12-31
    Enrolment
    187

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Vivax
    InterventionTafenoquine (TQ)
    PhaseNot recorded
    Registry statusCompleted